Neogenix Oncology Files Patent Application For the 16C3 Antigen

GREAT NECK, N.Y.--(BUSINESS WIRE)-- Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

The Company believes, based on in vitro and animal studies, that the 16C3 antibody has anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company intends to explore as it moves towards preparation of a pre-IND package for FDA review and design of a 16C3 antibody clinical trial.

“There is an ongoing need to identify new targets and to develop new diagnostic tools and novel therapies for life-threatening illnesses, especially colorectal and pancreatic cancer, where opportunities exist to significantly improve treatment outcomes and survival rates. The goal of our program is to discover and develop compounds/products that are highly specific, are well differentiated, and that may someday lead to improved diagnostics and therapeutics. Future research with 16C3 will determine if this antibody will meet those criteria,” said Neogenix President and Chief Executive Officer, Philip M. Arlen, MD.

The USPTO recently issued a Notice of Allowance for the Company’s patent application related to the 16C3 antibody. The USPTO previously issued a patent for the company’s NPC-1C monoclonal antibody and has allowed claims in a related divisional patent application relating to the genes encoding the novel molecular aspects of NPC-1C. The Company has also recently filed a patent application with the USPTO for the NPC-1C antigen.

Additional information regarding Neogenix Oncology can be found at www.neogenix.com.

About Neogenix Oncology

Neogenix Oncology is a development stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NPC-1C antibody in patients with metastatic pancreatic and colorectal cancer.

Forward Looking Statements Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the Form 10 of Neogenix Oncology. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

RMT PR Management
RoseMarie Terenzio
(o) 212-414-1909
(c) 917-913-7226
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.